AION labs advances antibody design with combinAble.AI
2 mins
Published by: Markus Ivakha
20 March 2024, 12:10PM
AION Labs launched CombinAble.AI to enhance antibody design using AI technology.
The platform integrates advanced machine learning models and computational methods for automated antibody optimization.
CombinAble addresses challenges in therapeutic antibody design, aiming to streamline the discovery of new therapeutics.
Daria Kokh, Co-Founder and CEO of CombinAble, emphasizes the importance of AI in enhancing antibody discovery.
The platform's goal is to revolutionize targeted antibody design, reducing time and costs in drug development through AI-driven optimization.
AION Labs Advances Antibody Design with CombinAble.AI
AION Labs introduced CombinAble.AI, a startup aimed at improving antibody design using AI technology. The platform combines advanced machine learning models and computational methods to automate antibody optimization, making the discovery process faster and more effective.
Our emphasis is on combining various advanced machine learning models, including large protein language models, molecular dynamics simulations and multi-objective optimization algorithms, integrating them into a single unified solution for targeted antibody discovery. AION Labs’ resources and expertise have been pivotal in shaping our company, providing the material and logistical support to help us refine our scientific strategy, and expand the team. As we progress, the knowledge and insights provided by its pharmaceutical partners will be invaluable for the development and commercialization of our solution.
CombinAble was created following an AION Labs’ startup challenge to develop an AI solution for therapeutic antibodies. The platform integrates AI technology and computational simulations to select mutations that enhance antibody characteristics, streamlining the discovery of new therapeutics.
Daria Kokh, Co-Founder and CEO of CombinAble, highlighted the importance of combining advanced machine learning models to enhance antibody discovery. The platform's goal is to transform the traditional trial-and-error process into a single, efficient solution.
Antibody optimization is crucial in drug development, and CombinAble's approach aims to reduce time and costs associated with the process. By leveraging AI and data from AION Labs’ partners, CombinAble is revolutionizing targeted antibody design.
The launch of CombinAble heralds a shift in the approach to targeted antibody design by leveraging AI to optimize and expedite the discovery process. We are delighted to welcome CombinAble into the AION Labs ecosystem and look forward to working closely with the team to develop solutions that enable the design of highly effective biological therapeutics.
User Comments
There are no reviews here yet. Be the first to leave review.
Hi, there!
Tags:
